Onesource Specialty Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Onesource Specialty Pharma Limited announced its audited financial results for Q4 and FY ended March 2026. The Board approved the results and declared an unmodified opinion from auditors Deloitte Haskins & Sells. The company also announced appointment of B S R & Co LLP as new statutory auditors for 5 years from the 19th AGM, replacing Deloitte Haskins & Sells whose term ends. The consolidated results include 6 subsidiaries (including step-down subsidiaries), with subsidiary total revenues of Rs. 1,192.89 million for the year and Rs. 303.38 million for Q4. The Group reported consolidated net profit after tax of Rs. 53.73 million for FY and Rs. 81.27 million for Q4, though other comprehensive loss was Rs. 71.19 million for the year.
Clean audit with unmodified opinion indicates no financial reporting concerns. Change in auditors from Deloitte to B S R & Co LLP reflects routine transition. Shareholders should note the consolidated net profit despite other comprehensive losses at the Group level.